Is Indaptus Therapeutics Inc (INDP) Stock About to Get Hot Tuesday?

The market has been high on Indaptus Therapeutics Inc (INDP) stock recently. INDP gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Indaptus Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on INDP!

See Full INDP Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With INDP Stock Today?

Indaptus Therapeutics Inc (INDP) stock is higher by 3% while the S&P 500 is down -0.47% as of 10:04 AM on Tuesday, Sep 19. INDP is higher by $0.11 from the previous closing price of $3.68 on volume of 13,578 shares. Over the past year the S&P 500 is up 13.66% while INDP is higher by 37.32%. INDP lost -$1.75 per share in the over the last 12 months. To screen for more stocks like Indaptus Therapeutics Inc click here.

More About Indaptus Therapeutics Inc

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York. Click Here to get the full Stock Report for Indaptus Therapeutics Inc stock.